zatosetron

structure given in first source; RN given refers to parent cpd

Also Known As:

5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-7-benzofurancarboxamide; LY 277359; LY 277359 maleate; LY-277359; zatosetron maleate; 7-Benzofurancarboxamide, 5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - zatosetron: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzofurans: 26
      - zatosetron: 5

Related Diseases

1.	Acute Pain 03/01/1994 - "Although several limitations of this study exist, these data documenting a lack of benefit of intravenously-administered zatosetron in alleviating the acute pain of migraine add to the list of 5-HT3 receptor antagonists that have failed to support efficacy of this therapeutic modality in the acute treatment of migraine."
2.	Migraine Disorders (Migraine) 03/01/1994 - "Likewise, no statistically significant differences between placebo and zatosetron treatment groups were identified with regard to migraine duration, overall migraine severity or the relief medication required. " 03/01/1994 - "Migraine severity was reduced in both the placebo and zatosetron groups with no statistically significant differences between zatosetron and placebo. " 03/01/1994 - "Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine." 03/01/1994 - "Zatosetron (13 mg or 0.19 mg/kg), a potent and selective 5-HT3 receptor antagonist was studied with a 30 min infusion in a crossover double-blind placebo-controlled trial for acute migraine therapy. " 03/01/1994 - "Although several limitations of this study exist, these data documenting a lack of benefit of intravenously-administered zatosetron in alleviating the acute pain of migraine add to the list of 5-HT3 receptor antagonists that have failed to support efficacy of this therapeutic modality in the acute treatment of migraine."
3.	Vomiting 02/01/1995 - "Clinical signs of toxicity characterized by salivation, diarrhea or soft stools, and/or emesis occurred in animals that received 10 or 25 mg/kg of zatosetron. " 03/01/1994 - "In dogs, zatosetron inhibited ipecac-induced emesis in a dose-dependent manner with a 100-micrograms/kg dose producing complete inhibition. " 03/01/1994 - "Zatosetron treatment inhibited and delayed ipecac-induced emesis in both groups. " 03/01/1994 - "Effect of zatosetron on ipecac-induced emesis in dogs and healthy men." 05/01/1995 - "Zatosetron and tropisetron significantly inhibited cisplatin-evoked emesis in dogs (estimated ID50 values of 34.4 +/- 2.3 micrograms/kg and 108.3 +/- 4.8 micrograms/kg i.v., respectively). "
4.	Neoplasms (Cancer) 03/01/1994 - "Our study demonstrates that zatosetron has similar efficacy on ipecac-induced emesis in healthy men, as has been shown previously with other 5-HT3 receptor antagonists in chemotherapy-induced emesis in cancer patients. "
5.	Diarrhea 02/01/1995 - "Clinical signs of toxicity characterized by salivation, diarrhea or soft stools, and/or emesis occurred in animals that received 10 or 25 mg/kg of zatosetron. "

Related Drugs and Biologics

1.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
2.	Ipecac (Syrup of Ipecac)
3.	Emetics
4.	Cisplatin (Platino)
5.	Antiemetics
6.	Tropisetron (Navoban)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)